Faderl Stefan, Thomas Deborah A, O'Brien Susan, Garcia-Manero Guillermo, Kantarjian Hagop M, Giles Francis J, Koller Charles, Ferrajoli Alessandra, Verstovsek Srdan, Pro Barbara, Andreeff Michael, Beran Miloslav, Cortes Jorge, Wierda William, Tran Ngoc, Keating Michael J
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA.
Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9.
We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11+ months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.
我们探讨了利妥昔单抗联合阿仑单抗治疗复发或难治性淋巴系统恶性肿瘤患者的安全性和疗效。48例患者接受了治疗并可评估疗效（32例慢性淋巴细胞白血病[CLL]、9例CLL/幼淋巴细胞白血病[PLL]、1例PLL、4例套细胞白血病/淋巴瘤、2例Richter转化）。总缓解率为52%（完全缓解8%；结节性部分缓解4%；部分缓解40%）。中位随访6.5个月（范围1 - 20个月），中位疾病进展时间为6个月（范围1 - 20个月）；中位生存期11个月（缓解者为11 +个月，未缓解者为6个月）。多数毒性反应为2级或以下且与输注相关。52%的患者发生感染。27%的患者巨细胞病毒（CMV）抗原血症检测呈阳性，但仅15%有症状且需要治疗。利妥昔单抗和阿仑单抗联合使用是可行的，具有可接受的安全性，并且在一组预后较差的患者中短期应用具有临床活性。
